← DSP Mutual Fund

DSP Nifty Healthcare ETF

Index/ETF Data as of Aug 2026 Comparing Jul 2026 → Aug 2026
Share: WhatsApp X
Stocks Held
20
Aug 2026
Equity Holdings
₹18.11 Cr
Equity only, excl. debt & cash
Top 5 Weight
49.8%
High concentration
Top 10 Weight
77.3%
High concentration
Changes
20
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
80.7% of portfolio
Launch Date
11 Jan 2024
2 years old
📋 What Happened This Month Among existing holdings, Divi's Laboratories Limited saw the biggest increase — now at 10.34% of the portfolio. Lupin Limited was trimmed the most, now at 4.57%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 80.7%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Jun 2026 Jul 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 78.6% 79.8% +1.2%
Healthcare Services 21.3% 20.0% -1.3%
Jul 2026 Aug 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 79.8% 80.7% +0.9%
Healthcare Services 20.0% 19.3% -0.8%
Biggest Add
Divi's Laboratories Limited
+1.46% · now 10.34%
Biggest Trim
Lupin Limited
-0.52% · now 4.57%

What Changed in the Portfolio This Month?

Comparing Jul 2026 → Aug 2026

Jul 2026 Aug 2026
↑ 8 Increased ↓ 12 Decreased
#StockSectorJul 2026Aug 2026Change
1
Divi's Laboratories Limited
₹1.87 Cr
Pharmaceuticals & Biotechnology 8.88% 10.34% +1.46%
2
Aurobindo Pharma Limited
₹74.04 L
Pharmaceuticals & Biotechnology 3.80% 4.09% +0.29%
3
Glenmark Pharmaceuticals Limited
₹58.16 L
Pharmaceuticals & Biotechnology 2.92% 3.21% +0.29%
4
Laurus Labs Limited
₹1.16 Cr
Pharmaceuticals & Biotechnology 6.13% 6.41% +0.28%
5
IPCA Laboratories Limited
₹42.74 L
Pharmaceuticals & Biotechnology 2.11% 2.36% +0.25%
6
Piramal Pharma Limited
₹20.77 L
Pharmaceuticals & Biotechnology 1.06% 1.15% +0.09%
7
Zydus Lifesciences Limited
₹45.24 L
Pharmaceuticals & Biotechnology 2.45% 2.50% +0.05%
8
Syngene International Limited
₹11.86 L
Healthcare Services 0.64% 0.65% +0.01%
#StockSectorJul 2026Aug 2026Change
1
Lupin Limited
₹82.79 L
Pharmaceuticals & Biotechnology 5.09% 4.57% -0.52%
2
Max Healthcare Institute Limited
₹1.21 Cr
Healthcare Services 7.10% 6.67% -0.43%
3
Cipla Limited
₹1.24 Cr
Pharmaceuticals & Biotechnology 7.19% 6.82% -0.37%
4
Alkem Laboratories Limited
₹48.55 L
Pharmaceuticals & Biotechnology 2.92% 2.68% -0.24%
5
Sun Pharmaceutical Industries Limited
₹3.27 Cr
Pharmaceuticals & Biotechnology 18.29% 18.07% -0.22%
6
Fortis Healthcare Limited
₹73.61 L
Healthcare Services 4.27% 4.06% -0.21%
7
Apollo Hospitals Enterprise Limited
₹1.43 Cr
Healthcare Services 8.00% 7.87% -0.13%
8
Torrent Pharmaceuticals Limited
₹1.16 Cr
Pharmaceuticals & Biotechnology 6.52% 6.39% -0.13%
9
Biocon Limited
₹45.79 L
Pharmaceuticals & Biotechnology 2.64% 2.53% -0.11%
10
Abbott India Limited
₹21.20 L
Pharmaceuticals & Biotechnology 1.27% 1.17% -0.10%

What Stocks Does This Fund Hold?

20 stocks — Aug 2026

# Stock Sector Cap Weight & Value
1
₹3.27 Cr
Pharmaceuticals & Biotechnology
18.07%
2
₹1.87 Cr
Pharmaceuticals & Biotechnology
10.34%
3
₹1.43 Cr
Healthcare Services
7.87%
4
₹1.24 Cr
Pharmaceuticals & Biotechnology
6.82%
5
₹1.21 Cr
Healthcare Services
6.67%
6
₹1.16 Cr
Pharmaceuticals & Biotechnology
6.41%
7
₹1.16 Cr
Pharmaceuticals & Biotechnology
6.39%
8
₹1.10 Cr
Pharmaceuticals & Biotechnology
6.05%
9
₹82.79 L
Pharmaceuticals & Biotechnology
4.57%
10
₹74.04 L
Pharmaceuticals & Biotechnology
4.09%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 DSP Mutual Fund — Portfolio & Holdings
See all funds managed by DSP Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.